Dr Schlechter on TAC01-HER2 Therapy in HER2+ Solid Tumors onclive.com/view/dr-schlec…

🎥Ben Schlechter of Dana-Farber highlights the promising results of TAC01-HER2 in the TACTIC-2 trial for solid tumors. Efficacy seen in GEJ cancer warrants further investigation with checkpoint inhibitors: ➡️ow.ly/WhTV50OOq5S⬅️ #ASCO23 ASCO

Interesting podcast (transcript) on the #qualityoflife of older #colorectalcancer patients medscape.com/viewarticle/98… by Ben Schlechter and Nadine McCleary #crcsm

🎥Ben Schlechter of Dana-Farber highlights challenges in CAR T-cell therapies for solid tumors. Safe targets such as CLDN18.2 show promise, while established receptors like HER2 can cause severe toxicity: ➡️ow.ly/mt9E50ORVfF⬅️ #ImmunoOnc #CAR-T #ASCO23 ASCO

It is shameful to see thinly veiled hate, inequality, racism, homophobia, bigotry, and anti-intellectualism enshrined in law by the United States Supreme Court.

I'm a doctor. My lane goes to every patient in every state in the US - no matter what the Supreme Court says. Do you really think this is about cake or webpages? So yes, this is me in my lane. lgbtmap.org/equality-maps/…

Episode 3: Treating Rectal Cancer: PROSPECT, PRODIGE, or OPRA? medscape.com/viewarticle/98…

via @NYTOpinion yes nytimes.com/2023/07/20/opi…

The artificial intelligence chatbot #ChatGPT has wowed some users with its seemingly human-like ability to generate and respond to language and worried others." Doug Rubinson & Ben Schlechter explore the potential benefits & challenges of ChatGPT in medicine: blog.dana-farber.org/insight/2023/0…

Our discussion on #HER2 #CRC medscape.com/viewarticle/98…

Jimmy Fund Telethon is on! Help us fight cancer and find a cure! danafarber.jimmyfund.org/goto/BenSchlec…

How do you know if your patient will benefit from liver-directed therapy for #colorectalcancer? Join experts Drs Ben Schlechter and AmmarSarwarIRad as they discuss. 🎧 #CCSM #OncTwitter ms.spr.ly/60129ZPmI

#her2 #gastriccancer Dana-Farber is now open and enrolling TACTIC-2, T-cell therapy for HER2+ gastric and esophageal cancers with at least one prior line of therapy. Great study to consider! clinicaltrials.gov/study/NCT04727…

Love science podcasts? If so, be sure to check out the Medscape #Colorectal Cancer Podcast segment, "Tumor Trash or Treasure #LiquidBiopsy for #Colorectal Cancer," by host Ben Schlechter with WCM Englander Institute for Precision Medicine's Dr. Pashtoon Kasi (Pashtoon Kasi MD, MS). medscape.com/viewarticle/10…

First effective use of immunotherapy for the most common subtype of #ColorectalCancer reported in Nature Medicine. This early-stage research shows promise for metastatic disease. #CancerResearch #ClinicalTrial CC: Dana-Farber Ben Schlechter Read more: ms.spr.ly/6016YAj9C

⭐ We spoke with Ben Schlechter of Dana-Farber on the unique mechanisms of action of botensilimab, and how this therapy is well-suited to treat microsatellite stable colorectal cancer, particularly in non-liver metastatic sites: buff.ly/4eKINoU

An alternative approach to CAR-T therapy in GI cancers is explored by Dr. Benjamin Schlechter Ben Schlechter Dana-Farber as he gives insight on clinical studies with TAC-T cells targeting HER2 and CLDN 18.2 #DAVAGI

d.pvroundup.com/12175RC01/1217…

The first day of poster presentations at #ASCO25 featured some of our expert insights into topics from trial progressions to risk factors for brain metastases in patients with metastatic breast cancer. Check out our full list here: bit.ly/43AGYpE